SINOMED(688108)2024-09-20 09:47Group 1: Financial Performance - In the first half of 2024, the company achieved operating revenue of 214 million yuan, representing a year-on-year growth of 32.49% [2] - The net profit attributable to shareholders of the listed company was -1,259.33 million yuan, with a significant increase of 125.88% [2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 766.20 million yuan, reflecting a year-on-year growth of 64% [2] Group 2: Investor Relations Activity - The investor relations activity took place on September 19, 2024, from 14:00 to 16:00 at the Shanghai Stock Exchange Roadshow Center [2] - Key personnel present included Shen Lihua (Director, CFO), Huang Kai (Director, Board Secretary), and Ma Yuan (Independent Director) [2] - The activity was categorized as a performance briefing for the first half of 2024 [2]